Abstract:
Nitazoxanide (NTZ) has bactericidal activity against the H37Rv laboratory strain of Mycobacterium tuberculosis (Mtb) with a minimum inhibitory concentration (MIC) of 16 μg/mL. However, its efficacy against clinical isolates of Mtb has not been determined. We found that NTZ’s MIC against 50 clinical isolates ranged from 12-28 μg/mL with a median of 16 μg/mL and was unaffected by resistance to first or second line anti-tuberculosis drugs or a diversity of spoligotypes.